13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001977548
Total reported value
$389.8M
$389.8M
10 檔
69.7%
In Q3 2025, Checkpoint Capital L.P.'s U.S. equity holdings reached a combined market value of $389.8M, distributed across 10 disclosed stock positions.
In Q3 2025, Checkpoint Capital L.P. adopted a defensive or profit-taking posture, trimming 4 positions and completely liquidating 6 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ARGX | Argenx Se - Adr | Stock-Healthcare | 37.07% | -8.85% | +0.02% | |
| 2 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 25.84% | -4.51% | -27.95% | |
| 3 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 10.92% | — | +14.08% | |
| 4 | IRON | Disc Medicine Inc | Stock-Other | 9.52% | -2.07% | +62.26% | |
| 5 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 7.70% | +10.56% | +75.82% | |
| 6 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 3.63% | -0.52% | EXIT | |
| 7 | SEPN | Septerna Inc | Stock-Other | 1.78% | -0.86% | EXIT | |
| 8 | STOK | Stoke Therapeutics Inc | Stock-Other | 1.67% | — | — | |
| 9 | KYMR | Kymera Therapeutics Inc | Stock-Other | 1.17% | — | -42.28% | |
| 10 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.69% | +6.12% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CORT | Corcept Therapeutics Inc | +10.6% | +14.08% | Add |
| 2 | IRON | Disc Medicine Inc | +2.9% | +62.26% | Add |
| 3 | RVMD | Revolution Medicines Inc | +0.1% | +75.82% | Add |
| 4 | ARGX | Argenx Se - Adr | -0.3% | +0.02% | Add |
| 5 | RYTM | Rhythm Pharmaceuticals Inc | -0.5% | -27.95% | Trim |
| 6 | SEPN | Septerna Inc | -0.8% | -51.72% | Trim |
| 7 | KYMR | Kymera Therapeutics Inc | -0.9% | -42.28% | Trim |
| 8 | STOK | Stoke Therapeutics Inc | -1% | — | Trim |
| 9 | SLNOEUR | Soleno Therapeutics Inc | — | EXIT | Sold out |
| 10 | CRNX | Crinetics Pharmaceuticals In | — | NEW | New buy |
| 11 | PTGX | Protagonist Therapeutics Inc | — | EXIT | Sold out |
| 12 | TCRX | Tscan Therapeutics Inc | — | EXIT | Sold out |
| 13 | CDTX | Cidara Therapeutics Inc | — | EXIT | Sold out |
| 14 | CYTK | Cytokinetics Inc | — | NEW | New buy |
| 15 | IMCR | Immunocore Holdings Plc-adr | — | EXIT | Sold out |
| 16 | ✓ | Rapt Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Checkpoint Capital L.P. reported a total U.S. public equity portfolio value of $389.8M across 10 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ARGX, RYTM, CORT) accounted for 69.7% of total reported equity market value during Q3 2025.
Top New Position Initiated
CRNX
市值: $10.8M
Top Position Liquidated / Trimmed
SLNOEUR
前期市值: $12.4M
During Q3 2025, Checkpoint Capital L.P.'s top holdings by market value included ARGX (37.1%)、RYTM (25.8%)、CORT (10.9%). The largest single position, ARGX, represented 37.1% of total portfolio value.
In Q3 2025, Checkpoint Capital L.P. made 16 total portfolio adjustments, initiating 2 new buys, adding to 4 positions, trimming 4 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.